Kymera Therapeutics Inc (KYMR) — Smart Money Tracker (13F, Q2 2026)

KYMR ranks #2230 out of 37503 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

KYMR is a top-conviction position for Atlas Venture Life Science Advisors, LLC — at 37.0% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in KYMR belongs to FMR LLC, but the position matters far more to Atlas Venture Life Science Advisors, LLC, who has 37.0% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Fidelity has added to its KYMR position for two straight quarters, increasing it by $721.4M to reach $1.4B today.

Adage Capital Partners Gp, L.l.c. has trimmed its KYMR position for two straight quarters, cutting it by $10.5M while still holding $22.9M.

KYMR is up 0.2% today, and institutions have been net buyers of $949.6M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

KYMR reported a net loss of $299.6M over the trailing twelve months.

• Not yet profitable — net loss of $299.6M over the trailing twelve months
• Revenue grew 134.8% year over year
• Net income declined year over year, from -$275.4M to -$299.6M
• Operating cash flow was negative, using $232.9M in cash
• Current ratio of 10.47x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.10x equity — within a conventional range